Kromek Investors - KMK

Kromek Investors - KMK

Best deals to access real time data!
Level 2 Basic
Monthly Subscription
for only
Monthly Subscription
for only
UK/US Silver
Monthly Subscription
for only
VAT not included
Stock Name Stock Symbol Market Stock Type
Kromek Group Plc KMK London Ordinary Share
  Price Change Price Change % Stock Price Last Trade
-0.20 -1.15% 17.25 10:23:33
Open Price Low Price High Price Close Price Previous Close
17.45 17.25 17.45 17.45
more quote information »
Industry Sector

Top Investor Posts

aqc888: Investors are probably a bit unnerved by the lack of information regarding the trials and quite a lot of unknowns regarding the detector. Not much definitive information seems to be released, I’d suspect the share price will continue to drift lower and stay between 15-19p. I’m satisfied with my holding as Kromek are valued at 24p by equity development without the detector. The rest of the business should perform better than it has for years due to the increased nuclear spending due to rise in instability in Afghanistan and the huge rise in the U.K. government nuclear spending previously mentioned. The medical scanner business is also performing better than it has in years. Even if the biological pathogen detector doesn’t work you’re only going to make modest losses, if any. The upside if the detector does work is huge however. Seems like there may well be no news on the biological pathogen detector till the end of the year
aqc888: Part of the purpose of an AGM is “ informing the members of previous and future activities”. So I’d hope that some ‘informingR17; regarding the biological pathogen detector will take place. With proper details investors can hang their hats on.
aqc888: I’ve got confidence the detector will work, but I’m getting a little nervous at no solid evidence. The kind of evidence that would please a lawyer. But then again that’s the kind of uncertainty that causes companies to be miss priced and where undervalued companies can be found. Lots of circumstantial evidence, but I suspect not enough for a professional investor - probably why most of Kromeks shareholders are private investors...
33mick: I think you are in the majority with your views Dave, and hopefully we'll all be given reassuring confirmation of the protocols ? NHS lab test result reports sometime soon. The investors here who have looked a little into the core RNA sequencing Platform tech being used by Kromek and its now widespread sale and use proven accuracy etc are maybe somewhat more relaxed with the impressive progress so far Kromek have made this year. They have rightly because of commercial sensetivtity witheld naming the actual 3rd party sequencing tech platform they are using. And hence it's rarely talked of here. Leaving investors to join the dots up so to speak. The ongoing development and advances in this novel UK miniaturised real time platform is all important , and for sure the unique market advantage here, but maybe not obvious to all as its firmly under wraps. The confidence regarding accuracy and operation spoken of many times now by Arnab and it's 30 minutes continuous results operation I don't doubt at all from researching the Sequencing technology in depth coupled with a track record of proven product design, using networked systems, with State of the art software use , product release and certification, a rock solid reputation with DARPA and the repeated development contracts means to many a more than balanced risk reward investment. Will there a few hiccups along the way, with this being a world first and the marriage of novel systems and software driven analysis? Of course there will be...there is in every new cutting edge new product development. But I'm quietly confident this will be eventually fully certified UK + States and on sale in various models and specifications at a very affordable cost price per unit.
aqc888: The ventilators are a perfect example of managements inability to communicate and manage investors expectations. I’m aware that at the start of the pandemic everybody including governments thought ventilators were the solution to people suffering with covid. However, as far as I’m aware the medical guidance changed and people suffering were given oxygen. Ventilators were only given to people in intensive care. There are not that many intensive care nurses and beds to go around. So having ventilators without the accompanying nurses was no use. So this was not a fault of Kromek. What is categorically the fault of management is not updating shareholders with this very reasonable explanation of what happened. The result of this is a very angry Que Passa who now disbelieves all the other things the management say. Another example of the failure of Kromeks management. If you can see through all this inept management. Then I think there’s an interesting company. A company in which a very experienced Simon Thompson has clearly identified as having huge value and upside. The problem is new investors have is that there is a huge queue of old fed up investors waiting to exit and keeping the share price suppressed
33mick: I bet the Navy s Covid problems were related to this latest MOD contract. Today's Proactive Investors comments. "Kromek targets record annual revenues after securing new contracts" "In Kromek’s new target area of biological-threat detection, the detection specialist has been awarded a £349,000 contract with the UK Ministry of Defence to develop its technology to meet defence and security" hTTps://
33mick: Just looked back to where the share price was when Kromek secured the first proof of concept DARPA contract at the end of 2018....26.5p..... So either the company with its cutting edge tech was over valued for most of the last few years......maybe...or as Its been mentioned by the likes of Investors Chronicle the Bio detection arm of the business is given no value by the market what so ever...mmmm "Kromek jumps as it secures bio-threat detection contract with DARPA 2018-12-10 07:27:00 The contract, which begins immediately and will run for 12 months, is to develop a proof-of-concept device for a vehicle-mounted biological-threat identifier." .................... .................... "The contract follows a previous win with DARPA in March when Kromek was awarded an extension of its high-volume production contract for its D3S nuclear detection devices. Shares were up 3.9% at 26.5p."(Dec 2018) hTTps://
aqc888: It makes me wonder how many other claims are being exaggerated by the CEO. This is one of Kromeks most important announcements to investors in years. Playing games and teasing investors with the release date of critical information is pretty poor corporate governance.
ch1ck: This is picking up coverage but it's in specialist mags this is from investors Chronicle earlier in the yearInvestors are rightly getting excited by Kromek's ground breaking prototype to sample air and identify the presence of any biological pathogen – including Covid-19 or any mutant version – that will be piloted in UK airports, hospitals and the retail sector in the coming months. It is based on Kromek's work in developing a mobile bio-security system capable of detecting airborne pathogens for an agency of the US Department of Defence. The detector is incredibly accurate, giving a false alarm in just one in 800,000 tests.Knowing a carrier is infected with a disease before they infect other individuals is key to halting the onset of an outbreak and will be critical in helping the world return to some form of normality even after the vaccine programme is rolled out. Other obvious non-military applications include use in sports arenas, theme parks, schools, offices and cruise ships. The fact that UK government agency Innovate UK is funding a £1.25m programme to customise Kromek's biological threat detection solution is a strong validation of the technology. Expect commercial roll-out later this year.COMPANIES June 14, 2021The Trader: FTSE hits post-pandemic high, Bitcoin leaps on Musk tweetThe potential profit windfall is simply not priced in, nor is the likelihood of Kromek returning to cash profitability in the 2021/22 financial year. Analyst Paul Hill at Equity Development values the annual global market for the biological threat detection devices at £500m and believes that Kromek could win a 20 per cent share on a 25 per cent profit margin, implying operating profit of £25m. Kromek only has a £45m market capitalisation. Moreover, with its working capital normalising, a £0.9m Covid-19 Paycheck loan set to be written off by the US Government, and a R&D tax credit of £1m due, then current net debt of £1.9m overstates the true position.
ch1ck: UK stocks are seen as extremely cheap at the moment. This is a Growing sector and I can see this being on a few radars for both investors and a possible tie-in partnership or even a takeover.I can see us back to 20p with a push to 30p this news today de risks the share and will pull in a few more new investors.Prepare for the ramping to start over the next few days.
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210920 10:19:25